Evidence map›Paper›PMID 41446562›Full record

ArticleContemporary clinical trials communications2025

A Bayesian model with seasonal effects for predicting accrual in clinical trials: Application to HOBIT and BOOST-3 trials for severe traumatic brain injury.

Mohammod Mahmudur Rahman, Md Saiful Islam Saif, Jonathan Beall, Renee' L Martin, Gaylan L Rockswold, William G Barsan, Frederick K Korley, Robert Silbergleit, Valerie Stevenson, Byron Gajewski

Registry-linked trialAbstract read
In one paragraph

Article in Contemporary clinical trials communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02407028 (Hyperbaric Oxygen Brain Injury Treatment), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02407028 phase2recruitingnot on this map

Hyperbaric Oxygen Brain Injury Treatment (HOBIT) Trial

TypeinterventionalSponsorGaylan RockswoldRan2018 to 2029Enrolled200ConditionsTraumatic Brain InjuryArmsHyperbaric oxygen (1.5 ATA, no NBH), Hyperbaric oxygen (2.0 ATA, no NBH), Hyperbaric oxygen (2.5 ATA, no NBH), Hyperbaric oxygen (1.5 ATA + NBH), Hyperbaric oxygen (2.0 ATA + NBH)
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mohammod Mahmudur RahmanDepartment of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA.
Md Saiful Islam SaifDepartment of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA.
Jonathan BeallDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.
Renee' L MartinDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.
Gaylan L RockswoldDepartment of Neurosurgery, University of Minnesota, Hennepin County Medical Center, Minneapolis, MN, USA.
William G BarsanDepartment of Emergency Medicine, University of Michigan, Ann Arbor, MI, USA.
Frederick K KorleyDepartment of Emergency Medicine, University of Michigan, Ann Arbor, MI, USA.
Robert SilbergleitDepartment of Emergency Medicine, University of Michigan, Ann Arbor, MI, USA.
Valerie StevensonDepartment of Emergency Medicine, University of Michigan, Ann Arbor, MI, USA.
Byron GajewskiDepartment of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA.

Funding

Brain Oxygen Optimization in Severe Traumatic Brain Injury - Phase 3 (BOOST-3)U01NS099046 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Ramon Diaz-Arrastia, Lori Shutter · 2018 to 2026
$35.7M
Hyperbaric Oxygen Brain Injury Treatment (HOBIT) Trial - CCCU01NS095926 · NINDS · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI Byron J. Gajewski, Frederick Kofi Korley · 2017 to 2026
$12.3M
NINDS NIH HHS U01 NS095926NINDS NIH HHS U01 NS099046
6 · The paper itself

Abstract

Background: Accurate accrual prediction is essential for initial planning and ongoing monitoring of clinical trials. Slow accrual can compromise statistical power, increase costs, or lead to premature trial termination. Traditional Bayesian approaches typically assume constant accrual rates and often fail to capture real-world seasonal fluctuations, which can reduce predictive accuracy. Methods: We developed a Bayesian seasonal accrual model that extends the traditional homogeneous model by incorporating quarter-specific priors to account for seasonal variation. The model combines prior knowledge with observed data up to the monitoring point to obtain accrual predictions using the Bayesian posterior predictive distribution. We applied this approach to quarterly accrual data from two ongoing trials: the Hyperbaric Oxygen Brain Injury Treatment (HOBIT) trial and the Brain Oxygen Optimization in Severe TBI Phase-3 (BOOST-3) trial. Along with the Deviance Information Criterion, model performance was evaluated using RMSE, bias, and standard deviation, calculated from internal predictions of total accruals within observed seasonal quarters. Posterior predictive distributions of accrual after 36 and 30 quarters were also generated. Results: Both trials exhibited seasonal trends, with the highest accrual rates in summer. The seasonal model yielded lower DIC in both trials. In HOBIT, internal prediction accuracy did not improve, likely due to uniformly low accrual rates. In contrast, the seasonal model outperformed the homogeneous model in BOOST-3 trial, yielding substantially lower RMSE, bias, and SD. Conclusion: Incorporating seasonal effects into accrual modeling can enhance prediction accuracy, particularly in larger trials with high enrollment, and supports more accurate trial forecasting and resource allocation.

Indexed as

Accrual predictionBrain oxygen optimization in severe TBI Phase-3 trialHyperbaric oxygen brain injury treatment trialSeasonal trend

Identifiers

PMID41446562
PMCPMC12723122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.